THIO, a first-in-class agent, targets telomeres, inducing cancer cell death and activating immune responses in NSCLC. The THIO-101 trial showed a median overall survival of 16.9 months, surpassing ...
As of January 15, 2025, third line (3L) data showed median overall survival (OS) of 16.9 months for the 22 NSCLC patients who received at least one dose of THIO (the intent-to-treat population ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback